A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

This study is testing a new drug called BEY1107 combined with capecitabine (an oral chemotherapy pill) in people with metastatic colorectal cancer that has not responded to at least two prior standard treatment regimens. **You may be eligible if...** - You have been diagnosed with colorectal cancer that has spread (metastatic) and cannot be removed by surgery - Your cancer progressed after at least two prior chemotherapy treatments including fluoropyrimidine, oxaliplatin, and irinotecan - You are 19 or older - You have at least one measurable tumor on scans - You are in reasonably good physical health (ECOG 0 or 1) - You are willing to use contraception if you can become pregnant or father a child **You may NOT be eligible if...** - You received chemotherapy, radiation, or biologic therapy recently (timeframe specified in the protocol) - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You have a history of serious allergic reactions to the study drugs Talk to your doctor to see if this trial is right for you.